Abstract
Cancer cell metabolism plays an important role in the progression of lung cancer. It is characterized through a shift from an oxidative to a glycolytic bioenergetics pathway, a phenomenon referred to as the warburg effect. However, the deregulation of miRNAs contributing to the warburg effect and to cancer cell metabolism is still unknown. In the present study, the results demonstrate that the expression of miR-202 is significantly decreased, and it induces a metabolic shift in lung cancer cells. miR-202 exerts this function through targeting HK2, resulting in the increase of glucose uptake and lactate production. The altered metabolism induced by miR-202 leads to cancer cell growth. These studies demonstrated that miR-202 may be involved in the metabolic shift via targeting HK2 in lung cancer cells.
Keywords: HK2, lung cancer, miR-202.
Current Signal Transduction Therapy
Title:miR-202 Mediates Metabolic Shift in Lung Cancer Cells via Targeting HK2
Volume: 9 Issue: 2
Author(s): Jin Li, Baohua Zhang, Qihuang Chen and Qiang Li
Affiliation:
Keywords: HK2, lung cancer, miR-202.
Abstract: Cancer cell metabolism plays an important role in the progression of lung cancer. It is characterized through a shift from an oxidative to a glycolytic bioenergetics pathway, a phenomenon referred to as the warburg effect. However, the deregulation of miRNAs contributing to the warburg effect and to cancer cell metabolism is still unknown. In the present study, the results demonstrate that the expression of miR-202 is significantly decreased, and it induces a metabolic shift in lung cancer cells. miR-202 exerts this function through targeting HK2, resulting in the increase of glucose uptake and lactate production. The altered metabolism induced by miR-202 leads to cancer cell growth. These studies demonstrated that miR-202 may be involved in the metabolic shift via targeting HK2 in lung cancer cells.
Export Options
About this article
Cite this article as:
Li Jin, Zhang Baohua, Chen Qihuang and Li Qiang, miR-202 Mediates Metabolic Shift in Lung Cancer Cells via Targeting HK2, Current Signal Transduction Therapy 2014; 9 (2) . https://dx.doi.org/10.2174/1574362410666150107234535
DOI https://dx.doi.org/10.2174/1574362410666150107234535 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nanoparticulate Drug Delivery Sytem for Cancer Therapy: Oppourtunities and Challenges
Recent Patents on Nanomedicine 3D QSAR of Aminophenyl Benzamide Derivatives as Histone Deacetylase Inhibitors
Medicinal Chemistry Synthesis and Evaluation of Haloacetyl, α-Bromoacryloyl and Nitrooxyacetyl Benzo[b]furan and Benzo[b]thiophene Derivatives as Potent Antiproliferative Agents Against Leukemia L1210 and K562 Cells
Letters in Drug Design & Discovery CAR T-cell Therapy: A New Era in Cancer Immunotherapy
Current Pharmaceutical Biotechnology Drug Repositioning Through Network Pharmacology
Current Topics in Medicinal Chemistry On the Comparison of Classifiers for Microarray Data
Current Bioinformatics ADAM9 as a Potential Target Molecule in Cancer
Current Pharmaceutical Design Herbal and Traditional Chinese Medicine for the Treatment of Cardiovascular Complications in Diabetes Mellitus
Current Diabetes Reviews Ursolic Acid in Cancer Treatment and Metastatic Chemoprevention: From Synthesized Derivatives to Nanoformulations in Preclinical Studies
Current Cancer Drug Targets STAT-1 and STAT-3: Closely Related Transcription Factors with Antagonistic Effects on Cell Proliferation and Apoptosis
Current Genomics JAK Inhibitors: Pharmacology and Clinical Activity in Chronic Myeloprolipherative Neoplasms
Current Medicinal Chemistry tcaSIM: A Simulation Program for Optimal Design of 13C Tracer Experiments for Analysis of Metabolic Flux by NMR and Mass Spectroscopy
Current Metabolomics Predictive Molecular Markers of Response to Epidermal Growth Factor Receptor(EGFR) Family-Targeted Therapies
Current Cancer Drug Targets Targeted Delivery of Anti-Inflammatory Agents to Tumors
Current Pharmaceutical Design Forodesine (BCX-1777, Immucillin H) - A New Purine Nucleoside Analogue: Mechanism of Action and Potential Clinical Application
Mini-Reviews in Medicinal Chemistry Relations between GPR4 Expression, Microvascular Density (MVD) and Clinical Pathological Characteristics of Patients with Epithelial Ovarian Carcinoma (EOC)
Current Pharmaceutical Design Proline Oxidase (POX) as A Target for Cancer Therapy
Current Drug Targets Cytotoxic and Apoptotic Effects of Novel Pyrrolo[2,3-d]Pyrimidine Derivatives Containing Urea Moieties on Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry New Chalcones Containing 5-Fluorouracil Exhibiting in vitro Anti-Cancer Activity
Letters in Organic Chemistry Wnt Signaling in Development, Disease and Translational Medicine
Current Drug Targets